MARKET

CANF

CANF

CAN FITE BIOPHAR
AMEX

Real-time Quotes | Nasdaq Last Sale

2.360
+0.150
+6.79%
Pre Market: 2.270 -0.09 -3.81% 09:05 02/25 EST
OPEN
2.250
PREV CLOSE
2.210
HIGH
2.490
LOW
2.180
VOLUME
4.76K
TURNOVER
--
52 WEEK HIGH
2.980
52 WEEK LOW
1.100
MARKET CAP
40.02M
P/E (TTM)
-1.4514
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
Zacks.com · 1d ago
Celsion, Citius Pharmaceuticals leads healthcare gainers; Otonomy, Brainstorm Cell Therapeutics among major losers
Gainers: Celsion CLSN +54%, SunLink Health Systems (SSY) +27%, Citius Pharmaceuticals (CTXR) +26%, Can-Fite BioPharma CANF +19%, Aesthetic Medical International Holdings Group (AIH) +18%.Losers: Otonomy OTIC -43%, Brainstorm Cell Therapeutics BCLI -32%, Re...
Seekingalpha · 2d ago
GME, CCIV, PBCT and VUZI among premarket gainers
ReTo Eco-Solutions (RETO) +132%.ATIF Holdings Limited (ATIF) +70% on establishing SPAC department to plan establishment of SPAC.Xcel Brands  (XELB) +52%.Celsion Corporation (CLSN) +48% after receiving FDA fast track designation for GEN-1.Can-Fite BioPharma
Seekingalpha · 3d ago
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?
NEW YORK, Feb. 22, 2021 /PRNewswire via COMTEX/ -- NEW YORK, Feb. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN,...
PR Newswire - PRF · 3d ago
Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows
Benzinga · 3d ago
Can-Fite soars 45% on positive namodenoson data in liver cancer
Can-Fite BioPharma (CANF) gains 45% premarket in reaction to the new data from the Phase II advanced liver cancer study including overall survival of nearly 4 years in two patients under namodenoson
Seekingalpha · 3d ago
BRIEF-New Positive Data From Can Fite Biopharma Ltd's Liver Cancer Phase II Clinical Study With Namodenoson
reuters.com · 3d ago
Can-Fite Biopharma Highlights New Data From Phase II Liver Cancer Study, Including Overall Survival Of ~4 Years In Two Patients Treated With Namodenoson; Says 'Namodenoson continues to demonstrate a good safety profile and is well tolerated'
Overall survival of nearly 4 years in two patients with disappearance of ascites, normal liver function, and good quality of life Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a
Benzinga · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CANF. Analyze the recent business situations of CAN FITE BIOPHAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CANF stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 356.04K
% Owned: 2.10%
Shares Outstanding: 16.96M
TypeInstitutionsShares
Increased
1
33.68K
New
3
224.94K
Decreased
4
5
Sold Out
1
913
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.05%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
Ilan Cohen
Chief Executive Officer/Director
Pnina Fishman
Chief Financial Officer/Chief Operating Officer
Motti Farbstein
Director
Guy Regev
Director
Abraham Sartani
Director
Israel Shamay
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About CANF
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.

Webull offers kinds of Can Fite Biopharma Ltd stock information, including AMEX:CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.